An investigation into the beneficial effects of high-dose interferon beta 1-a, compared to low-dose interferon beta 1-a in severe COVID-19: The COVIFERON II randomized controlled trial

INTRODUCTION: Coronavirus disease 2019 (COVID-19) has been a serious obstacle in front of public health. Interferon-beta 1a (IFN-β 1a) has been used to treat patients with COVID-19. We aimed to compare the effectiveness of high-dose IFN-β 1a compared to low dose IFN-β 1a in severe COVID-19 cases. ME...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Int Immunopharmacol
Autori principali: Alavi Darazam, Ilad, Hatami, Firouze, Mahdi Rabiei, Mohammad, Amin Pourhoseingholi, Mohamad, Shabani, Minoosh, Shokouhi, Shervin, Mardani, Masoud, Moradi, Omid, Javandoust Gharehbagh, Farid, Mirtalaee, Nasrinsadat, Negahban, Halimeh, Amirdosara, Mahdi, Zangi, Masoud, Hajiesmaeili, Mohammadreza, Kazempour, Muhanna, Shafigh, Navid
Natura: Artigo
Lingua:Inglês
Pubblicazione: Elsevier B.V. 2021
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8238656/
https://ncbi.nlm.nih.gov/pubmed/34224994
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.intimp.2021.107916
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi